Ex-vivo models of post-surgical residual disease in human glioblastoma
Open Access
- 4 November 2024
- journal article
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1316
Abstract
Background Glioblastoma is a highly infiltrative, currently incurable brain cancer. To date, translation of novel therapies for glioblastoma from the laboratory into clinical trials has relied heavily on in vitro cell culture and murine (subcutaneous and orthotopic) xenograft models using cells derived from the main bulk of patient tumours. However, it is the residual cells left-behind after surgery that are responsible for disease progression and death in the clinic. A lack of substantial improvements in patient survival for decades suggests commonly used murine xenograft models, a key step before clinical trials, do not reflect the biology of residual disease in patients. Methods To address this, we have developed the ‘Sheffield Protocol’ to generate ex vivo models that reflect both resected, and post-surgical residual disease from the same patient. The protocol leverages parallel derivation of inherently treatment-resistant glioblastoma stem cells (GSCs) from ‘core’ and distant ‘edge’ regions through careful macrodissection of a large en bloc specimen, such as from a partial lobectomy for tumour, followed by tissue dissociation and propagation in serum-free media. Opportunistic en bloc specimen use can liberate the most distant infiltrative cells feasibly accessible from living patients. Results We provide an example illustrating that resected and residual disease models represent spatially divergent tumour subpopulations harbouring distinct transcriptomic and cancer stem cell marker expression profiles. We also introduce the ‘Sheffield Living Biobank’ of glioma models (SLB) that incorporates over 150 GSC lines from 60+ patients, including 44+ resected and residual models, which are available for academic use via MTA. Conclusions These models provide a novel tool to reduce animal xenograft usage by improving candidate drug triage in early preclinical studies and directly replacing animal studies for some therapies that are post-Phase 1+ clinical trial for other cancers/conditions to, ultimately, deliver more effective treatments for post-surgical residual disease in glioblastoma.Keywords
Funding Information
- Royal College of Surgeons of England
- National Institute for Health and Care Research
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/T001895/1)
- Yorkshire's Brain Tumour Charity
- The Brain Tumour Charity (ET_2019/1_10403, FL_2021_/1_10610)
This publication has 68 references indexed in Scilit:
- Integrative spatial analysis reveals a multi-layered organization of glioblastomaCell, 2024
- Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspectiveCell, 2024
- SoxE group transcription factor Sox8 promotes astrocytic differentiation of neural stem/precursor cells downstream of NfiaPharmacology Research & Perspectives, 2021
- DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapiesMolecular Oncology, 2021
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Current trends in mouse models of glioblastomaJournal of Neuro-Oncology, 2017
- The Role of Peripheral Myelin Protein 2 in RemyelinationCellular and Molecular Neurobiology, 2017
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Elevated invasive potential of glioblastoma stem cellsBiochemical and Biophysical Research Communications, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010